Podcast
Questions and Answers
According to the study results, how much higher was the percentage of predicted FEV1 in patients who received elexacaftor-tezacaftor-ivacaftor compared to placebo at 4 weeks?
According to the study results, how much higher was the percentage of predicted FEV1 in patients who received elexacaftor-tezacaftor-ivacaftor compared to placebo at 4 weeks?
- 8.3 points higher
- 18.3 points higher
- 3.8 points higher
- 13.8 points higher (correct)
What was the rate of pulmonary exacerbations in patients who received elexacaftor-tezacaftor-ivacaftor compared to placebo?
What was the rate of pulmonary exacerbations in patients who received elexacaftor-tezacaftor-ivacaftor compared to placebo?
- 43% lower
- 53% lower
- 63% lower (correct)
- 73% lower
What was the minimum clinically important difference for the respiratory domain score on the Cystic Fibrosis Questionnaire–Revised?
What was the minimum clinically important difference for the respiratory domain score on the Cystic Fibrosis Questionnaire–Revised?
- 2 points
- 6 points
- 4 points (correct)
- 8 points
How much lower was the sweat chloride concentration in patients who received elexacaftor-tezacaftor-ivacaftor compared to placebo?
How much lower was the sweat chloride concentration in patients who received elexacaftor-tezacaftor-ivacaftor compared to placebo?
What was the publication date of the article?
What was the publication date of the article?
Which mutation is responsible for causing cystic fibrosis in nearly 90% of patients?
Which mutation is responsible for causing cystic fibrosis in nearly 90% of patients?
What is the primary end point of the phase 3 trial conducted to test the efficacy and safety of elexacaftor–tezacaftor–ivacaftor?
What is the primary end point of the phase 3 trial conducted to test the efficacy and safety of elexacaftor–tezacaftor–ivacaftor?
What are the three drugs used in combination in the phase 2 trial to improve Phe508del CFTR function and clinical outcomes?
What are the three drugs used in combination in the phase 2 trial to improve Phe508del CFTR function and clinical outcomes?
What age group was included in the phase 3 trial to test the efficacy and safety of elexacaftor–tezacaftor–ivacaftor?
What age group was included in the phase 3 trial to test the efficacy and safety of elexacaftor–tezacaftor–ivacaftor?
Where can the full names, academic degrees, and affiliations of the authors be found?
Where can the full names, academic degrees, and affiliations of the authors be found?
What is the purpose of the phase 3 trial mentioned in the text?
What is the purpose of the phase 3 trial mentioned in the text?
What were the drugs used in combination in the phase 2 trial to improve Phe508del CFTR function and clinical outcomes?
What were the drugs used in combination in the phase 2 trial to improve Phe508del CFTR function and clinical outcomes?
What was the primary end point of the phase 3 trial?
What was the primary end point of the phase 3 trial?
How old were the patients included in the phase 3 trial?
How old were the patients included in the phase 3 trial?
What is the gene mutation responsible for causing cystic fibrosis in nearly 90% of patients?
What is the gene mutation responsible for causing cystic fibrosis in nearly 90% of patients?
What was the percentage of predicted FEV1 that was higher in patients who received elexacaftor-tezacaftor-ivacaftor compared to placebo at 4 weeks?
What was the percentage of predicted FEV1 that was higher in patients who received elexacaftor-tezacaftor-ivacaftor compared to placebo at 4 weeks?
What was the rate of pulmonary exacerbations that was lower in patients who received elexacaftor-tezacaftor-ivacaftor compared to placebo?
What was the rate of pulmonary exacerbations that was lower in patients who received elexacaftor-tezacaftor-ivacaftor compared to placebo?
What was the respiratory domain score on the Cystic Fibrosis Questionnaire–Revised that was higher in patients who received elexacaftor-tezacaftor-ivacaftor compared to placebo?
What was the respiratory domain score on the Cystic Fibrosis Questionnaire–Revised that was higher in patients who received elexacaftor-tezacaftor-ivacaftor compared to placebo?
What was the sweat chloride concentration that was lower in patients who received elexacaftor-tezacaftor-ivacaftor compared to placebo?
What was the sweat chloride concentration that was lower in patients who received elexacaftor-tezacaftor-ivacaftor compared to placebo?
How many patients underwent randomization and received at least one dose of active treatment or placebo?
How many patients underwent randomization and received at least one dose of active treatment or placebo?
Flashcards are hidden until you start studying
